DOD - Department of Defense

Funding Organization

Awards Grant

  • Boosting the Systemic and in Situ CD4+ T-Cell Responses to Malignant Glioma by Oncolytic HSV Virotherapy
  • Dual PET/Fluorescence Imaging of Glioma with an MMP-14 Activabable Peptide Probe
  • Effects of ITGAM Genetic Variation on Mac-1 Mediated Functions of B Cells
  • Evaluation Of A Novel Hemostatic Agent In Junctional Trauma
  • Glycocalyx Mechanoregulation of Anglopoietln-2 and Post-Traumatic Lung Injury
  • Identification of Novel Ovarian Cancer Oncogenes that Function by Regulating Exosome Function
  • Immersive Virtual Walking as Treatment for Neuropathic Pain in Spinal Cord Injury: Examing Treatment Efficacy and Cortical Mechanisms
  • Improving Immune Response in Ovarian Cancer by Modulating the Wnt Pathway
  • Interactions of Gut Microbiome, Genetic Susceptibility and Environmental Factors in Parkinson's Disease
  • Interactions of Gut Microbiome, Genetic Susceptibility and Environmental Factors in Parkinson's Disease
  • Oncobioenergetics of Breast Carcinogenesis
  • Overcoming PAAP Inhibitor Resistance of BACA-Deficient Ovarian Cancers
  • Part B - Surviving Blood Loss: First in Human Studies to Assess Safety and Physiological Effects of Synthetic Ethinyl Estradiol-3-Sulfate (EE·3·SO4) in Healthy Subjects, Both Euvolemic and Following 10-20% Iatrogenic Blood Loss
  • Pharmacological Management of Ultraviolet Radiation Induced Skin Cancer
  • Research Acceleration to Maximize Warrior Performance (RAMP)
  • Sculpting Anti-tumor Immunity as an Approach to Treat Metastatic Breast Cancer
  • Targeting Homology-Directed Recombinational Repair (HDR) of Chromosomal Breaks to Sensitize Prostate Cancer Cells to Poly (ADP-Ribose) Polymerase (PARP) Inhibition
  • The Genomic, Epigenomic and Quality-of-Life Characteristics of Long-Term Survivors of Ovarian Cancer
  • The Neurofibromatosis Clinical Trials Consortium
  • Therapeutic Recovery of Immune and Lung Tissue Bioenergetic Homeostasis in Sepsis-Induced Immunosuppression
  • Treatment Of Recurrent, Platinum-Resistant Ovarian Cancer With Glutaminase 1 And PARP Inhibitors